AR078049A1 - Moduladores de lxr - Google Patents
Moduladores de lxrInfo
- Publication number
- AR078049A1 AR078049A1 ARP100101870A ARP100101870A AR078049A1 AR 078049 A1 AR078049 A1 AR 078049A1 AR P100101870 A ARP100101870 A AR P100101870A AR P100101870 A ARP100101870 A AR P100101870A AR 078049 A1 AR078049 A1 AR 078049A1
- Authority
- AR
- Argentina
- Prior art keywords
- lxr modulators
- compounds
- lxr
- modulators
- pharmaceutical use
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Toxicology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Compuestos, sales aceptables para uso farmacéutico, isomeros, o profármacos de los mismos, que son utiles como moduladores de la actividad de los receptores hepáticos X (LXR). También se revelan composiciones farmacéuticas que contienen los compuestos y usos de los mismos. Reivindicacion 1: Un compuesto, isotopo, o sal aceptable para uso farmacéutico del mismo, seleccionado de la Tabla (1).
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18173609P | 2009-05-28 | 2009-05-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR078049A1 true AR078049A1 (es) | 2011-10-12 |
Family
ID=43223342
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100101870A AR078049A1 (es) | 2009-05-28 | 2010-05-28 | Moduladores de lxr |
Country Status (31)
| Country | Link |
|---|---|
| US (4) | US8618154B2 (es) |
| EP (1) | EP2435410B1 (es) |
| JP (1) | JP5625050B2 (es) |
| KR (1) | KR101676704B1 (es) |
| CN (1) | CN102648184B (es) |
| AR (1) | AR078049A1 (es) |
| AU (1) | AU2010254082B2 (es) |
| BR (1) | BRPI1013259B8 (es) |
| CA (1) | CA2761934C (es) |
| CL (1) | CL2011002972A1 (es) |
| CO (1) | CO6470826A2 (es) |
| CY (1) | CY1119407T1 (es) |
| DK (1) | DK2435410T3 (es) |
| EA (1) | EA019960B1 (es) |
| ES (1) | ES2620451T3 (es) |
| HR (1) | HRP20170194T1 (es) |
| IL (1) | IL216176A (es) |
| LT (1) | LT2435410T (es) |
| MX (1) | MX2011012559A (es) |
| MY (1) | MY153958A (es) |
| NZ (1) | NZ596330A (es) |
| PE (1) | PE20120797A1 (es) |
| PL (1) | PL2435410T3 (es) |
| PT (1) | PT2435410T (es) |
| SG (1) | SG176247A1 (es) |
| SI (1) | SI2435410T1 (es) |
| SM (1) | SMT201700253T1 (es) |
| TN (1) | TN2011000585A1 (es) |
| TW (1) | TWI488844B (es) |
| WO (1) | WO2010138598A2 (es) |
| ZA (1) | ZA201108181B (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SMT201700253T1 (it) * | 2009-05-28 | 2017-07-18 | Bristol Myers Squibb Co | Modulatori di lxr |
| TW201242953A (en) * | 2011-03-25 | 2012-11-01 | Bristol Myers Squibb Co | Imidazole prodrug LXR modulators |
| SI2820013T1 (sl) | 2012-03-02 | 2018-11-30 | Ralexar Therapeutics, Inc, | Modulatorji jetrnega x receptorja za zdravljenje dermalnih bolezni, motenj in stanj |
| JP6320382B2 (ja) * | 2012-08-13 | 2018-05-09 | ザ ロックフェラー ユニヴァーシティ | メラノーマの処置および診断 |
| JP6456909B2 (ja) | 2013-03-15 | 2019-01-23 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｌｘｒ調節因子 |
| US9834542B2 (en) | 2013-03-15 | 2017-12-05 | Bristo-Myers Squibb Company | LXR modulators |
| EP3041834A4 (en) | 2013-09-04 | 2017-01-18 | Ralexar Therapeutics, Inc. | Liver x receptor (lxr) modulators |
| RS60479B1 (sr) | 2013-09-04 | 2020-08-31 | Ellora Therapeutics Inc | Modulatori receptora x jetre (lxr) |
| US10669296B2 (en) | 2014-01-10 | 2020-06-02 | Rgenix, Inc. | LXR agonists and uses thereof |
| KR101815734B1 (ko) | 2015-05-29 | 2018-01-05 | 가톨릭대학교 산학협력단 | ｍｉＲ－７, ｍｉＲ－１８ａ 또는 ｍｉＲ－１８ｂ를 유효성분으로 포함하는 대사성 질환의 예방 또는 치료용 약학적 조성물 |
| AU2017207291B2 (en) | 2016-01-11 | 2023-06-15 | The Rockefeller University | Methods for the treatment of myeloid derived suppressor cells related disorders |
| AU2018373028A1 (en) | 2017-11-21 | 2020-04-30 | Inspirna, Inc. | Polymorphs and uses thereof |
| JP2022541013A (ja) | 2019-07-15 | 2022-09-21 | ノバルティス アーゲー | 肝臓ｘ受容体アゴニストでマイボーム腺機能不全を治療するための方法 |
| CN110305141B (zh) * | 2019-07-18 | 2022-01-11 | 深圳市三启药物开发有限公司 | 一种螺(3,3’-异丙基吡咯烷氧化吲哚)类肝x受体调节剂及其制备方法和应用 |
| MX2022007164A (es) | 2019-12-13 | 2022-09-12 | Inspirna Inc | Sales metálicas y usos de estas. |
| CN115656401B (zh) * | 2022-11-09 | 2025-03-28 | 武汉海特生物创新医药研究有限公司 | 一种咪唑-4-甲酸乙酯纯度的hplc检测方法 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4231938A (en) | 1979-06-15 | 1980-11-04 | Merck & Co., Inc. | Hypocholesteremic fermentation products and process of preparation |
| US4444784A (en) | 1980-08-05 | 1984-04-24 | Merck & Co., Inc. | Antihypercholesterolemic compounds |
| DK149080C (da) | 1980-06-06 | 1986-07-28 | Sankyo Co | Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre |
| WO1984002131A1 (fr) | 1982-11-22 | 1984-06-07 | Sandoz Ag | Produits analogues de mevalolactone et leurs derives, leurs procedes de production, compositions pharmaceutiques les contenant ainsi que leur utilisation en tant que produits pharmaceutiques |
| US5354772A (en) | 1982-11-22 | 1994-10-11 | Sandoz Pharm. Corp. | Indole analogs of mevalonolactone and derivatives thereof |
| FI94339C (fi) | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
| US5177080A (en) | 1990-12-14 | 1993-01-05 | Bayer Aktiengesellschaft | Substituted pyridyl-dihydroxy-heptenoic acid and its salts |
| ATE215601T1 (de) | 1991-09-17 | 2002-04-15 | Salk Inst For Biological Studi | Rezeptoren der steroid/thyroid superfamilie von rezeptoren |
| EP1019059A4 (en) | 1997-01-24 | 2004-01-14 | Univ California | USE OF FXR, PPAR-ALPHA AND LXR-ALPHA ACTIVATORS TO RESTORE THE BARRIER FUNCTION, TO PROMOTE EPIDERMIS DIFFERENTIATION, AND TO PROLIFERATE |
| AU5994199A (en) | 1998-09-23 | 2000-04-10 | Alexander Mata De Urquiza | Analysis of ligand activated nuclear receptors (in vivo) |
| JP2002532729A (ja) | 1998-12-23 | 2002-10-02 | グラクソ グループ リミテッド | 核内受容体のリガンドのアッセイ |
| DE60029029T2 (de) | 1999-03-26 | 2007-06-14 | City Of Hope, Duarte | Screenen nach FXR-Rezeptormodulatoren |
| IL147022A0 (en) | 1999-06-18 | 2002-08-14 | Cv Therapeutics Inc | Compositions and methods for increasing cholesterol efflux and raising hdl using atp binding cassette transporter protein abc1 |
| WO2001082917A2 (en) | 2000-05-03 | 2001-11-08 | Tularik Inc. | Treatment of hypertriglyceridemia and other conditions using lxr modulators |
| US6924311B2 (en) | 2001-10-17 | 2005-08-02 | X-Ceptor Therapeutics, Inc. | Methods for affecting various diseases utilizing LXR compounds |
| US7482366B2 (en) * | 2001-12-21 | 2009-01-27 | X-Ceptor Therapeutics, Inc. | Modulators of LXR |
| AU2003263814A1 (en) * | 2002-07-26 | 2004-02-16 | Bayer Pharmaceuticals Corporation | Indane, dihydrobenzofuran, and tetrahydronaphthalene carboxylic acid derivatives and their use as antidiabetics |
| TWI324596B (en) * | 2002-08-26 | 2010-05-11 | Nat Health Research Institutes | Imidazolamino compounds |
| CN1795179A (zh) * | 2003-05-27 | 2006-06-28 | 科学研究和应用咨询公司 | 新的咪唑衍生物、其制备方法和其作为药物的用途 |
| JP5095216B2 (ja) * | 2003-11-14 | 2012-12-12 | ローラス セラピューティクス インコーポレーテッド | アリールイミダゾールおよびその抗癌剤としての使用 |
| EP1713799A4 (en) * | 2004-02-11 | 2010-07-07 | Irm Llc | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF LXR |
| CN101248048B (zh) * | 2005-06-27 | 2013-08-28 | 埃克塞利希斯专利有限责任公司 | 吡唑基lxr调节剂 |
| ES2525217T3 (es) * | 2005-06-27 | 2014-12-19 | Exelixis Patent Company Llc | Moduladores de LXR basados en imidazol |
| KR20090094125A (ko) | 2006-12-08 | 2009-09-03 | 엑셀리시스, 인코포레이티드 | Ｌｘｒ 및 ｆｘｒ 조절자 |
| SMT201700253T1 (it) * | 2009-05-28 | 2017-07-18 | Bristol Myers Squibb Co | Modulatori di lxr |
-
2010
- 2010-05-26 SM SM20170253T patent/SMT201700253T1/it unknown
- 2010-05-26 BR BRPI1013259A patent/BRPI1013259B8/pt not_active IP Right Cessation
- 2010-05-26 US US13/319,937 patent/US8618154B2/en not_active Expired - Fee Related
- 2010-05-26 WO PCT/US2010/036211 patent/WO2010138598A2/en not_active Ceased
- 2010-05-26 AU AU2010254082A patent/AU2010254082B2/en not_active Ceased
- 2010-05-26 PT PT107219024T patent/PT2435410T/pt unknown
- 2010-05-26 EA EA201171488A patent/EA019960B1/ru not_active IP Right Cessation
- 2010-05-26 ES ES10721902.4T patent/ES2620451T3/es active Active
- 2010-05-26 SI SI201031427A patent/SI2435410T1/sl unknown
- 2010-05-26 DK DK10721902.4T patent/DK2435410T3/da active
- 2010-05-26 PE PE2011002005A patent/PE20120797A1/es active IP Right Grant
- 2010-05-26 NZ NZ596330A patent/NZ596330A/xx unknown
- 2010-05-26 EP EP10721902.4A patent/EP2435410B1/en active Active
- 2010-05-26 MY MYPI2011006278A patent/MY153958A/en unknown
- 2010-05-26 SG SG2011087459A patent/SG176247A1/en unknown
- 2010-05-26 LT LTEP10721902.4T patent/LT2435410T/lt unknown
- 2010-05-26 PL PL10721902T patent/PL2435410T3/pl unknown
- 2010-05-26 HR HRP20170194TT patent/HRP20170194T1/hr unknown
- 2010-05-26 CA CA2761934A patent/CA2761934C/en active Active
- 2010-05-26 CN CN201080033601.2A patent/CN102648184B/zh not_active Expired - Fee Related
- 2010-05-26 KR KR1020117031397A patent/KR101676704B1/ko not_active Expired - Fee Related
- 2010-05-26 MX MX2011012559A patent/MX2011012559A/es active IP Right Grant
- 2010-05-26 JP JP2012513215A patent/JP5625050B2/ja not_active Expired - Fee Related
- 2010-05-28 TW TW099117252A patent/TWI488844B/zh not_active IP Right Cessation
- 2010-05-28 AR ARP100101870A patent/AR078049A1/es not_active Application Discontinuation
-
2011
- 2011-11-07 IL IL216176A patent/IL216176A/en active IP Right Grant
- 2011-11-08 ZA ZA2011/08181A patent/ZA201108181B/en unknown
- 2011-11-16 TN TNP2011000585A patent/TN2011000585A1/en unknown
- 2011-11-24 CL CL2011002972A patent/CL2011002972A1/es unknown
- 2011-11-25 CO CO11161736A patent/CO6470826A2/es active IP Right Grant
-
2013
- 2013-11-21 US US14/085,926 patent/US20140163081A1/en not_active Abandoned
-
2015
- 2015-05-04 US US14/703,247 patent/US20150299136A1/en not_active Abandoned
-
2016
- 2016-06-07 US US15/175,425 patent/US20160280661A1/en not_active Abandoned
-
2017
- 2017-04-05 CY CY20171100403T patent/CY1119407T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR078049A1 (es) | Moduladores de lxr | |
| AR088728A1 (es) | Moduladores de lxr como prodroga de imidazol | |
| AR093244A1 (es) | Compuestos de benceno sustituidos utilizables en el tratamiento de trastornos mediados por ezh2 | |
| CO6150138A2 (es) | Ciclobuten-1,2-dionas 3,4-di-sustituidas como ligandos de receptores de quimiocinas cxc | |
| AR110056A2 (es) | Modulación de receptores quimiosensoriales y ligandos relacionados con los mismos | |
| AR056873A1 (es) | Derivados de pirazolopirimidinas como inhibidores de quinasa dependientes de ciclina, composiciones farmaceuticas | |
| GT201600085A (es) | Composiciones y métodos para modular los receptores x farnesoides | |
| CO6620055A2 (es) | Ciertas amino-pirimidinas, composiciones de las mismas y métodos para el uso de los mismos | |
| CL2013002821A1 (es) | Compuestos derivados de pirrolo[2,3-d]pirimidina; composicion farmaceutica que los comprende; y su uso como antagonista de los receptores tropomiosina (trk) para el tratamiento del dolor. | |
| UY32156A (es) | Derivados sustituidos de la n2 - [1-(5 - fluoropirimidin -2-il) etil] - n4 - (1-metil - 1h-imidazol - 4 - il)) - pirimidina - 2,4 - diaminas y sus sales farmacéuticamente aceptables, proceso de preparación, composiciones conteniéndolos y aplicaciones. | |
| DOP2010000229A (es) | Compuestos que comprenden un grupo ciclobutoxi | |
| UY31918A (es) | Compuestos de pirazol inhibidores de fgfr, composiciones farmaceuticas que los comprenden, procesos para su preparacion y su uso como medicamento | |
| UY33380A (es) | Formulaciones farmacéuticas que contienen derivados de 1-(b(beta)-d-glucopiranosilo) y sus usos | |
| PE20151423A1 (es) | Derivados tetrahidropiranilo inhibidores del hcv | |
| CU20110204A7 (es) | Compuestos 1-cianoetilheterociclilcarboxamida sustituidos 750 | |
| UY31048A1 (es) | Nuevos compuestos de pirimidina y usos de los mismos | |
| UY33655A (es) | Co-cristales y sales de inhibidores de ccr30 | |
| UY36651A (es) | Compuestos antiestrogénicos | |
| UY31885A (es) | Derivados de las 1, 3, 5-triazina-2, 4-diaminas-6-sustituidas-n-sustituidas y sales farmacéuticamente aceptables de los mismos, composiciones y aplicaciones. | |
| CR20130671A (es) | Antagonistas de trpv4 | |
| NI201300072A (es) | Derivados de heteroarilo como moduladores nachr alfa 7 | |
| MX340360B (es) | Formulaciones farmaceuticas que comprenden derivados de nitrocatecol y metodos para hacer las mismas. | |
| CR20140218A (es) | Compuestos de 1,2,5-oxadiazol sustituido y su uso como herbicidas iii | |
| GT200800285A (es) | Aminopirazolopiridinas sustituidas y sus sales, sus preparaciones y composiciones farmaceuticas que las comprenden | |
| CL2017002354A1 (es) | Compuestos derivados de heteroarilos bicíclicos fusionados con actividad como inhibidores de phd. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal | ||
| FB | Suspension of granting procedure |